Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis

  • MAbs. 2017 Aug/Sep;9(6):927-944. doi: 10.1080/19420862.2017.1332553.
Alain P Vicari  1 ,  Alain M Schoepfer  2 ,  Bertrand Meresse  3 ,  Laurence Goffin  1 ,  Olivier Léger  4 ,  Soheila Josserand  5 ,  Nicolas Guégan  3 ,  Shida Yousefi  6 ,  Alex Straumann  7 ,  Nadine Cerf-Bensussan  3 ,  Hans-Uwe Simon  6 ,  Yolande Chvatchko  1
Affiliations
  • 1. a Calypso Biotech SA , Plan-les-Ouates , Switzerland.
  • 2. b Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois (CHUV) , Lausanne , Switzerland.
  • 3. c INSERM U1163, Institut Imagine , Paris , France.
  • 4. d Olivier Léger , Saint Sixt , France.
  • 5. e Novimmune , Plan-les-Ouates , Switzerland.
  • 6. f Institute of Pharmacology, University of Bern, Inselspital , Bern , Switzerland.
  • 7. g Swiss EoE Clinic and EoE Research Network , Olten , Switzerland.
PMID: 28581883 DOI: 10.1080/19420862.2017.1332553
Abstract

Interleukin-15 (IL-15) is a critical regulator of immune responses, especially at mucosal interfaces within the gastro-intestinal tract. Here, we describe the discovery and characterization of a humanized antibody to IL-15. Data from its epitope and mode of action, Cell Biology and primate pharmacology, as well as translational studies in human samples and in vivo proof-of-concept experiments in mouse models demonstrate the therapeutic potential of this new antibody targeting IL-15 for refractory Celiac Disease and eosinophilic Esophagitis.

Keywords
Antibody; IL-15; celiac disease; cis; eosinophilic esophagitis; humanized; interleukin-15; trans.
Products